Glucuronic Acid

Glucuronic Acid

SCHEMBL7089004

O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.73
LMNA P02545 2/20 0.52
USP2 O75604 1/20 0.47
SLCO1B1 Q9Y6L6 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 2/20 0.41
CYP2C9 P11712 1/20 0.41
OR51E2 Q9H255 1/20 0.33
AKR1B1 P15121 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KDM4E B2RXH2 2/20 0.32
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glucuronic Acid SCHEMBL3686871 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL14841816 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Glucuronic Acid SCHEMBL8675875 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Glucuronic Acid SCHEMBL2365643 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL861904 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL20741140 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL2785483 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Glucuronic Acid SCHEMBL10823159 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL4389427 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1
Gluconic Acid SCHEMBL20815121 1.00 PDE4A (0.73) PDE4ALMNAUSP2SLCO1B1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020103370-A1 Genetic control of acetylation and pyruvylation of xanthan based polysaccharide polymers DOHERTY DANIEL H (US) 2002-08-01 US claimed
US-6316614-B1 GENERATION OF WATER-SOLUBLE POLYSACCHARIDE; OBTAIN A MUTANT OF XANTHAMONAS, CULTURE THE MUTANT, AND RECOVER POLYSACCHARIDE CP KELCO U.S., INC. 2001-11-13 US claimed
US-5948651-A ISOLATING ACETYLASE DEFICIENT MUTANT OF MICROORGANISM, AND CULTURING TO PRODUCE BIOPOLYMER WITH UNITS OF D-GLUCOSE:D-MANNOSE:D-GLUCURONIC ACID RATIO OF 2:2:1 WITH SPECIFIC LINKAGE CONFIGURATIONS MONSANTO COMPANY (US) 1999-09-07 US claimed
EP-0511690-B1 Family of xanthan-based polysaccharide polymers including non-acetylated and/or non-pyruvylated gum GETTY SCIENT DEV CO (US) 1997-07-30 EP claimed
EP-0765939-A2 Family of xanthan-based polysaccharide polymers including non-acetylated and/or non-pyruvylated gum GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1997-04-02 EP claimed
US-5514791-A BIOSYNTHESIS, MUTANTS, VISCOSIFIERS OF WATER GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1996-05-07 US claimed
EP-0410326-A2 Genetic control of acetylation and pyruvylation of xanthan gum GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1991-01-30 EP claimed
EP-0584206-B1 GENETIC CONTROL OF ACETYLATION OF XANTHAN BASED POLYSACCHARIDE POLYMERS MONSANTO CO (US) 2003-07-30 EP disclosed
US-20020103370-A1 Genetic control of acetylation and pyruvylation of xanthan based polysaccharide polymers DOHERTY DANIEL H (US) 2002-08-01 US disclosed
US-20020103370-A1 Genetic control of acetylation and pyruvylation of xanthan based polysaccharide polymers DOHERTY DANIEL H (US) 2002-08-01 US disclosed
US-6316614-B1 GENERATION OF WATER-SOLUBLE POLYSACCHARIDE; OBTAIN A MUTANT OF XANTHAMONAS, CULTURE THE MUTANT, AND RECOVER POLYSACCHARIDE CP KELCO U.S., INC. 2001-11-13 US disclosed
US-5948651-A ISOLATING ACETYLASE DEFICIENT MUTANT OF MICROORGANISM, AND CULTURING TO PRODUCE BIOPOLYMER WITH UNITS OF D-GLUCOSE:D-MANNOSE:D-GLUCURONIC ACID RATIO OF 2:2:1 WITH SPECIFIC LINKAGE CONFIGURATIONS MONSANTO COMPANY (US) 1999-09-07 US disclosed
US-5514791-A BIOSYNTHESIS, MUTANTS, VISCOSIFIERS OF WATER GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1996-05-07 US disclosed
US-5514791-A BIOSYNTHESIS, MUTANTS, VISCOSIFIERS OF WATER GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1996-05-07 US disclosed
EP-0584206-A1 GENETIC CONTROL OF ACETYLATION AND PYRUVYLATION OF XANTHAN BASED POLYSACCHARIDE POLYMERS GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1994-03-02 EP disclosed
WO-1992019753-A1 GENETIC CONTROL OF ACETYLATION AND PYRUVYLATION OF XANTHAN BASED POLYSACCHARIDE POLYMERS GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1992-11-12 WO disclosed
EP-0410326-A2 Genetic control of acetylation and pyruvylation of xanthan gum GETTY SCIENTIFIC DEVELOPMENT COMPANY (US) 1991-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103370-A1 Genetic control of acetylation and pyruvylation of xanthan based polysaccharide polymers UGGT1, GALK1, GALE PDE4A 1995/4885LMNA 1637/4885USP2 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.